NIH CLINICAL CENTER GRAND ROUNDS
Episode 2011-12
Time: 01:03:45
Recorded March 23, 2011

PARP Inhibitors: How Successful Have We Been in Modulating DNA Damage?
Shivaani Kummar, MD
Head, Early Clinical Trials Development, Office of the Director, Division of Cancer Treatment and Diagnosis, NCI

The Evolving Role of PARP Inhibitors in Breast and Ovarian Cancers
Elise C. Kohn, MD
Head, Medical Ovarian Cancer Clinic, and Head, Molecular Signaling Section, Medical Oncology Branch, Center for Cancer Research, NCI

ANNOUNCER: Discussing Outstanding Science of the Past, Present and Future - this is NIH Clinical Center Grand Rounds.

(Music establishes, goes under voice over)

Welcome to the NIH Clinical Center Grand Rounds, recorded March 23, 2011 at the Clinical Center at the National Institutes of Health in Bethesda, Maryland—an agency of the United States Department of Health and Human Services. Today's speakers, both from the National Cancer Institute, will address aspects of PARP inhibitors. Our first speaker is Dr. Shivaani Kummar. Her topic is "How Successful Have We Been in Modulating DNA Damage." Dr. Elise Kohn will follow. She will address "The Evolving Role of PARP Inhibitors in Brest and Ovarian Cancers."

You can see a closed-captioned videocast of this lecture by logging onto http://videocast.nih.gov -- click the "Past Events" link -- or by clicking the "View Videocast" link on the podcast homepage at www.cc.nih.gov/podcast. The NIH CLINICAL CENTER GRAND ROUNDS podcast is a presentation of the NIH Clinical Center, Office of Communications, Patient Recruitment and Public Liaison. For more information about the NIH Clinical Center, America's clinical research hospital, log onto http://clinicalcenter.nih.gov.

For persons with disabilities or those using assistive technology requiring additional assistance with the podcast should contact us at martinon@cc.nih.gov.